

Baseline characteristics of participants in FORTIFY: a Phase 3 study to evaluate safety, tolerability, and efficacy of BBP-418 in LGMD2I/R9 (*FKRP*-related)



Ada Lee, MD, Amy Rainey, Tricia Blankenbiller, Lindsay Reklis, Douglas Sproule MD, MSc, Tahseen Mozaffar, MD¹, Katherine Mathews, MD¹, and Volker Straub, MD¹ on behalf of the FORTIFY Study Investigators. ML Bio Solutions, a BridgeBio Pharma Inc. company, Palo Alto, CA, USA
¹ FORTIFY Trial Investigator



Introduction

- FORTIFY (NCT05775848) will evaluate the efficacy and safety of BBP-418 in individuals with limb girdle muscular dystrophy type 2I, R9 FKRP-related (LGMD2I/R9), a disease for which no approved therapies currently exist.
- BBP-418 is an investigational therapy intended to saturate the partially functional FKRP enzyme with substrate and potentially stabilize or improve muscular function.
- The study enrolled 112 individuals with genetically confirmed LGMD2I/R9 and is being conducted at 22 sites globally (see Figure 1). The study includes participants aged 12 to 60 years in the US, UK and Australia and 18 to 60 years in the EU.

Study Sites and Baseline Characteristics

Figure 1. FORTIFY Global Clinical Trial Sites




Table 1. FORTIFY Baseline Characteristics

Age (years)	
Mean (SD)	35.8 (14.22)
12-<18 [n (%)]	15 (13.4%)
18-60 [n (%)]	97 (86.6%)
Sex	
Male [n (%)]	53 (47.3%)
Female [n (%)]	59 (52.7%)
Race ¹	
White [n (%)]	108 (96.4%)
Black [n (%)]	1 (0.9%)
Multiple [n (%)]	3 (2.7%)
Ethnicity	
Hispanic or Latino [n (%)]	5 (4.5%)
Not Hispanic or Latino [n (%)]	107 (95.5%)
Genotype	
Homozygous (L276I) [n (%)]	83 (74.1%)
Other FKRP [n (%)]	29 (25.9%)
Baseline functional testing ²	
NSAD [n, mean (SD)]	104, 28.1 (13.9)
100 MTT (s) [n, mean (SD)]	92, 112.2 (127.9)
FVC % predicted [n, mean (SD)]	100, 76.9 (17.3)
10 MWT (s) [n, mean (SD)]	96, 10.2 (7.8)
PUL 2.0 Total [n, mean (SD)]	104, 38.9 (3.5)


¹Asian, Native Hawaiian or Other Pacific Islander, American Indian or Alaska Native, and Other races were not seen in this study.
²Baseline functional testing is based upon the primary efficacy set, which contains 104 individuals. The primary efficacy set is defined as randomized individuals who have an NSAD≥3 at baseline.
Data shown is PRELIMINARY and may change. BBP-418 is an investigational product and is not approved for use by any health regulatory authorities.

Abbreviations

10 MWT, 10-meter walk test; 100 MTT, 100-meter timed test; αDG, alpha dystroglycan; CK, creatine kinase; ECG, electrocardiogram; EU, European Union; FKRP, fukutin-related protein; FVC, forced vital capacity; LGMD2I/R9, Limb-girdle muscular dystrophy type 2I, R9 FKRP-related; NSAD, North Star Assessment for Dysferlinopathy (also referred to as the North Star Assessment for Limb Girdle Muscular Dystrophy); PUL2.0, Performance of Upper Limb 2.0; QTc, corrected QT interval; SAEs, serious adverse events; TEAEs, treatment-emergent adverse events; UK, United Kingdom; US, United States

Study Design

Figure 2. FORTIFY Study Design Schematic



Eligibility

Key Inclusion Criteria*

- have a genetically confirmed diagnosis of LGMD2I/R9 & be clinically affected
- male or female participants 12 to 60 years of age (inclusive)**
- willing and able to complete all study procedures, including muscle biopsies



Key Exclusion Criteria*

- evidence of clinically significant concomitant disease
- score of zero on any one or more of the primary or key secondary endpoints at the time of screening***
- use of ribose or other sugar alcohol-containing supplement within 90 days of screening
- use of a systemic corticosteroid within 90 days of screening
- previously received gene therapy to treat LGMD2I/R9 experimental therapy or device within 90 days of screening



*Additional inclusion and exclusion criteria apply.
**Applicable to participants in US, UK, and AUS only. In EU, male or female participants 18 to 60 years of age (inclusive) are eligible.
***Not applicable to individuals who participated in ML Bio's natural history study MLB-01-001 (NCT04202627).

Study Endpoints

Primary Endpoint

Efficacy

- Change from baseline in NSAD at 36 months

Safety

- Frequency and severity of TEAEs and treatment-emergent SAEs
- Results of physical examinations including vital signs
- Chemistry and hematology laboratory analyses
- 12-lead ECG, including QTc intervals

Key Biomarker Objectives	Secondary Endpoints
- Change from baseline in glycosylated αDG - Change from baseline in serum CK obtained before functional assessment	- Change from baseline in 100 MTT at 36 months - Change from baseline in PUL2.0 at 36 months - Change from baseline in FVC (% predicted, performed in a sitting position) at 36 months - Change from baseline in 10 MWT (velocity) at 36 months

Conclusions

- FORTIFY is an ongoing randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the safety and efficacy of BBP-418, an oral investigational therapy, as a potential therapy for LGMD2I/R9.
- Efficacy and safety will be evaluated through assessments of physical, cardiac, and respiratory function, as well as biomarker endpoints.
- The trial enrolled 112 participants across 22 sites globally, and baseline characteristics are presented here for the first time.
- For more information on FORTIFY, visit <https://clinicaltrials.gov/study/NCT05775848>

Acknowledgements & Disclosures

- The authors would like to thank the study participants and their families for their participation in FORTIFY, as well as the investigators and trial staff involved in FORTIFY.
- FORTIFY is sponsored and funded by ML Bio Solutions Inc., a BridgeBio Pharma, Inc. company, Palo Alto, CA, USA.
- AL, AR, TB, LR, and DS are employees of ML Bio Solutions Inc., a BridgeBio company, and may have equity compensation packages as part of such employment.